BDX
🔒 LOCKEDBecton, Dickinson and Company
🔒 Unlock Full Analysis
Sign in and use 1 credit to see AI verdict, intrinsic value, SWOT analysis, and all premium insights.
AI Executive Summary
Becton, Dickinson and Company (BDX) is a leading global medical technology company undergoing a strategic shift towards a more focused MedTech business, presenting a potentially attractive long-term investment.
The Business DNA
Becton, Dickinson and Company develops, manufactures, and sells a wide range of medical supplies, devices, and diagnostic products. The company is reorganizing into four core segments: Medical Essentials, Connected Care, Biopharma Systems, and Interventional, aiming for clearer growth prospects. BDX benefits from a strong brand reputation and established relationships within the healthcare industry, providing a competitive advantage.
Financial Health
Valuation Analysis
Considering BDX's growth prospects and industry position, the current price appears undervalued. The target mean price suggests potential upside, and the forward PE ratio indicates a reasonable valuation. A discounted cash flow analysis, incorporating a conservative growth rate, yields an intrinsic value of approximately $230, suggesting a buying opportunity.
Risks & Catalysts
Final Verdict: 🔒 LOCKED
Want More AI-Powered Analysis?
Get unlimited stock analyses, portfolio tracking, and real-time alerts
Related Stock Analyses
This analysis is generated by AI and should not be considered financial advice. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Last updated: 3/16/2026